NURS FPX 4060 Assessment 4 Health Promotion Plan Presentation
Student Name
Capella University
NURS-FPX 4060 Practicing in the Community to Improve Population Health
Prof. Name
Date
Health Promotion Plan
Introduction
Hello, my name is ________, and I serve as a community nurse. I welcome you to today’s session, which focuses on Human Papillomavirus (HPV), a highly prevalent sexually transmitted infection.
This health education session is designed to strengthen public understanding of Human Papillomavirus (HPV), with emphasis on its epidemiology, disease burden, and evidence-based prevention strategies. From a community nursing perspective, the goal is to enhance awareness, reduce transmission risk, and improve long-term health outcomes through structured health promotion interventions.
Key aims of this session include:
- Improving knowledge of HPV transmission and complications
- Supporting informed decision-making regarding vaccination and screening
- Promoting preventive sexual health behaviors
- Reducing stigma associated with HPV diagnosis
Introduction to HPV
What is HPV?
Human Papillomavirus (HPV) refers to a large family of non-enveloped DNA viruses that primarily infect epithelial tissues of the skin and mucosal surfaces. More than 200 distinct HPV genotypes have been identified, of which approximately 40 are sexually transmitted and associated with anogenital infection (Soheili et al., 2021).
HPV is recognized as the most widespread sexually transmitted infection globally, with the majority of sexually active individuals exposed at some point in their lives (El-Zein et al., 2019). While many infections are transient and asymptomatic, persistent infection with high-risk strains can lead to malignancies.
Clinical relevance of high-risk HPV includes:
- Cervical cancer
- Oropharyngeal cancer
- Anal and genital cancers
- Persistent genital warts (low-risk types)
Why is awareness important?
HPV infection often remains clinically silent for extended periods, which contributes to delayed diagnosis and increased transmission risk. Although many infections resolve spontaneously, persistent high-risk strains significantly increase cancer risk (WHO, 2023).
Importance of awareness includes:
- Early detection through screening programs
- Prevention via vaccination
- Reduction in cancer-related morbidity and mortality
- Improved sexual health literacy
Key preventive actions:
- HPV vaccination before sexual debut
- Routine cervical screening (Pap/HPV testing)
- Safe sexual practices (condom use, partner reduction)
Prevalence of HPV
Who is affected by HPV and how common is it?
HPV represents a major global public health concern. In the United States alone, approximately 42 million individuals were infected in 2018, with around 13 million new infections annually (HPV, 2023).
High-risk demographic:
- Adolescents and young adults (15–25 years), accounting for nearly 75% of new infections (Clarke et al., 2021)
How does prevalence differ between genders?
HPV affects all genders; however, clinical outcomes vary due to biological and behavioral differences.
- Women: Higher risk of cervical cancer development
- Men: Increased risk of oropharyngeal and anal cancers
Annually:
- ~21,000 women develop HPV-related cancers
- ~15,000 men develop HPV-related complications
- ~4,000 female deaths occur due to HPV-related disease (HPV, 2023)
What other factors influence prevalence?
Table 1: Determinants of HPV Prevalence
| Factor | Key Observation |
|---|---|
| Socioeconomic status | Higher prevalence in low- and middle-income populations |
| Geographic variation | Southern and Midwestern U.S. show higher infection rates (Hirth et al., 2019) |
| Age | Peak incidence in ages 15–25 |
| Gender | Cervical disease more common in females; throat cancers more common in males |
Additional epidemiological insights:
- Global cervical cancer mortality: ~342,000 deaths in 2020 (WHO, 2023)
- Oral HPV prevalence: 5.0% in men vs. 3.6% in women (Yu et al., 2023)
NURS FPX 4060 Assessment 4 Health Promotion Plan Presentation
Impact of HPV
How does HPV affect health?
HPV has multidimensional health consequences that extend beyond infection.
Physical impact:
- Cervical, anal, penile, vulvar, and oropharyngeal cancers
- Genital warts
- Chronic infection-related complications (Kombe et al., 2021)
Psychological impact:
- Anxiety and emotional distress
- Stigma and shame following diagnosis
- Fear of cancer progression (Chadwick et al., 2022)
Social impact:
- Social withdrawal
- Reduced intimacy and relationship strain
Financial impact:
- High costs of screening and treatment
- Economic burden of cancer care, especially in low-income populations (Chesson et al., 2021)
What strategies help reduce the impact?
Evidence-based interventions focus on prevention and early detection.
Effective strategies include:
- HPV vaccination programs
- Community-based health education
- Routine screening (Pap smear and HPV testing)
- Counseling and psychosocial support
Nurses play a central role by:
- Providing patient education
- Encouraging vaccination uptake
- Supporting screening adherence
- Reducing stigma through counseling (Luttjeboer et al., 2023)
Evidence-Based Health Promotion Plan
How can nurses contribute to HPV prevention?
Nurses act as primary health educators in HPV prevention by delivering structured, evidence-based interventions.
Core nursing roles:
- Health education workshops
- Distribution of informational materials
- Digital health awareness campaigns
- Addressing misconceptions and vaccine hesitancy (Rodríguez et al., 2019)
What community-based interventions are effective?
Effective population-level strategies include:
- School-based vaccination programs
- Youth-centered sexual health education
- Free community screening services
- Parent-adolescent counseling programs
These interventions have demonstrated improved vaccination rates and reduced HPV transmission risk (Bastani et al., 2021; Pathak et al., 2022).
SMART Goals of Health Promotion Plan
What are the SMART goals for HPV prevention?
SMART goals ensure structured, measurable progress in health promotion interventions (Bailey, 2019).
Table 2: SMART Goals for Patient (Maria)
| Goal Area | Specific Goal | Timeline |
|---|---|---|
| Financial protection | Reduce healthcare-related financial burden by 60% through awareness of assistance programs | 6 months |
| Health education | Attend 6 structured HPV education sessions (online + in-person) | 3 months |
| Social well-being | Participate in HPV support group to reduce stigma and isolation | Ongoing |
| Emotional health | Attend weekly counseling sessions for coping and resilience building | 3 months |
Educational Outcomes of SMART Goals
Structured education improves:
- HPV knowledge and health literacy
- Vaccine acceptance and preventive behavior
- Emotional coping mechanisms
- Access to healthcare services
Participation in workshops and counseling enhances psychological resilience and reduces anxiety related to diagnosis (Santos et al., 2022).
How can educational sessions be improved?
Table 3: Strategies for Program Enhancement
| Improvement Area | Strategy |
|---|---|
| Cultural sensitivity | Adapt materials to cultural and religious contexts |
| Accessibility | Expand digital and in-person learning platforms |
| Evaluation methods | Use quizzes, feedback forms, and interactive discussions |
| Language inclusion | Provide multilingual resources |
| Healthcare integration | Coordinate with primary care providers |
| Peer learning | Include survivor testimonials |
| Digital engagement | Use social media influencers and credible health voices |
Healthy People 2030 Objectives and Leading Health Indicators
How does the plan align with national health objectives?
The Healthy People 2030 framework emphasizes:
- 90% HPV vaccination coverage in adolescents
- 70% cervical cancer screening coverage in women aged 35–45
- Increased treatment coverage for HPV-related conditions (U.S. Department of Health and Human Services, 2023)
This health promotion plan aligns by:
- Increasing preventive awareness
- Enhancing screening participation
- Supporting vaccine uptake
- Addressing health inequities
Health Policies to Achieve Established Goals
Which policies support HPV prevention?
Key supportive policies include:
- Affordable Care Act (ACA): Expands access to preventive services
- Medicaid programs: Support low-income populations with vaccination and screening coverage
These policies strengthen:
- Preventive healthcare access
- Equity in health services
- Early intervention and cancer prevention (Raymond et al., 2021)
Future Changes in Educational Sessions
How can educational sessions be enhanced?
Future improvements should focus on scalability and engagement:
- Expansion of online interactive learning modules
- Integration of real-time quizzes and digital feedback
- Increased use of multilingual educational tools
- Inclusion of peer-led storytelling approaches
- Collaboration with healthcare professionals for consistency
- Engagement of trusted public figures for awareness campaigns
These approaches improve reach, retention, and behavioral change outcomes (Wong et al., 2020; Leung et al., 2019; Olusanya et al., 2021; Lewis et al., 2021).
Conclusion
HPV remains one of the most prevalent sexually transmitted infections globally, particularly affecting individuals aged 15–25 years. Persistent high-risk HPV strains are strongly associated with multiple cancers, creating significant physical, psychological, social, and financial burdens.
A comprehensive health promotion plan that integrates:
- Vaccination
- Screening
- Health education
- Counseling
- Community engagement
can substantially reduce HPV-related disease burden. Alignment with Healthy People 2030 ensures evidence-based, equitable, and sustainable prevention strategies.
References
Bailey, R. (2019). Goal setting and action planning for health behavior change. American Journal of Lifestyle Medicine, 13(6), 615–618. https://doi.org/10.1177/1559827617729634
Bastani, R., Glenn, B. A., Singhal, R., Crespi, C. M., Nonzee, N. J., Tsui, J., … Taylor, V. M. (2021). Increasing HPV vaccination among low-income, ethnic minority adolescents: Effects of a multicomponent system intervention through a county health department hotline. Cancer Epidemiology, Biomarkers & Prevention, 31(1), 175–182. https://doi.org/10.1158/1055-9965.EPI-20-1578
Chadwick, V., Bennett, K. F., McCaffery, K. J., Brotherton, J. M. L., & Dodd, R. H. (2022). Psychosocial impact of testing human papillomavirus positive in Australia’s HPV-based cervical screening program: A cross-sectional survey. Psycho-Oncology, 31(7), 1110–1119. https://doi.org/10.1002/pon.5897
Chesson, H. W., Laprise, J.-F., Brisson, M., Martin, D., Ekwueme, D. U., & Markowitz, L. E. (2021). The estimated lifetime medical cost of diseases attributable to human papillomavirus infections acquired in 2018. Sexually Transmitted Diseases. https://doi.org/10.1097/OLQ.0000000000001379
NURS FPX 4060 Assessment 4 Health Promotion Plan Presentation
Clarke, M. A., Risley, C., Stewart, M. W., Geisinger, K. R., Hiser, L. M., Morgan, J. C., … Wentzensen, N. (2021). Age-specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort. Cancer Medicine, 10(23), 8641–8650. https://doi.org/10.1002/cam4.4340
El-Zein, M., Coutlée, F., Tellier, P.-P., Roger, M., Franco, E. L., & Burchell, A. N. (2019). Human papillomavirus infection and transmission among couples through heterosexual activity (HITCH) cohort study: Protocol. JMIR Research Protocols, 8(1), e11284. https://doi.org/10.2196/11284
Hirth, J. M., Kuo, Y.-F., Starkey, J. M., Rupp, R. E., Laz, T. H., Rahman, M., & Berenson, A. B. (2019). Regional variations in human papillomavirus prevalence across time in NHANES (2003–2014). Vaccine, 37(30), 4040–4046. https://doi.org/10.1016/j.vaccine.2019.06.001
HPV. (2023, March). National Foundation for Infectious Diseases. https://www.nfid.org/infectious-disease/hpv/
Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G.-A., Zhou, Y., & Jin, T. (2021). Epidemiology and burden of human papillomavirus and related diseases. Frontiers in Public Health, 8, 552028. https://doi.org/10.3389/fpubh.2020.552028
Luttjeboer, J., Simons, J. J. M., Westra, T. A., Wilschut, J., Boersma, C., Postma, M. J., & van. (2023). An updated analysis of the impact of HPV vaccination based on long-term effectiveness in the Netherlands. Infectious Diseases and Therapy, 12(8), 2135–2145. https://doi.org/10.1007/s40121-023-00851-9
Rodríguez, L., Barrios, M., Pachón, C., & Lugo, E. (2019). Educational intervention on human papillomavirus in university students. Indian Journal of Community Medicine, 44(3), 213. https://doi.org/10.4103/ijcm.ijcm_247_18
NURS FPX 4060 Assessment 4 Health Promotion Plan Presentation
Santos, P. D., Melly, P., Hilfiker, R., Giacomino, K., Perruchoud, E., Verloo, H., & Pereira, F. (2022). Effectiveness of educational interventions to increase skills in evidence-based practice among nurses: The EDITCare systematic review. Healthcare, 10(11), 2204. https://doi.org/10.3390/healthcare10112204
Soheili, M., Keyvani, H., Soheili, M., & Nasseri, S. (2021). Human papillomavirus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment. Medical Journal of the Islamic Republic of Iran. https://doi.org/10.47176/mjiri.35.65
Sundaram, N., Voo, T. C., & Tam, C. C. (2019). Adolescent HPV vaccination: Empowerment, equity, and ethics. Human Vaccines & Immunotherapeutics, 16(8), 1835–1840. https://doi.org/10.1080/21645515.2019.1697596
U.S. Department of Health and Human Services. (2023). Healthy People 2030. https://health.gov/healthypeople
Vorsters, A., Bosch, F. X., Poljak, M., Waheed, D.-N., Stanley, M., & Garland, S. M. (2022). HPV prevention and control – The way forward. Preventive Medicine, 156, 106960. https://doi.org/10.1016/j.ypmed.2022.106960
World Health Organization. (2023, November 17). Cervical cancer. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
NURS FPX 4060 Assessment 4 Health Promotion Plan Presentation
Yu, S., Zhu, Y., He, H., Hu, Y., Zhu, X., Diao, W., Li, S., Shan, G., & Chen, X. (2023). Prevalence and risk factors of oral human papillomavirus infection among healthy adults in Hebei, China. BMC Infectious Diseases, 23(1), 773. https://doi.org/10.1186/s12879-023-08759-y